Pan Yinlong, Wu Mengmeng, Cai Huazhong
Department of Emergency, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Department of Anesthesiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Front Cell Dev Biol. 2024 Nov 5;12:1446418. doi: 10.3389/fcell.2024.1446418. eCollection 2024.
Over 90% of treatment failures in cancer therapy can be attributed to multidrug resistance (MDR), which can develop intracellularly or through various routes. Numerous pathways contribute to treatment resistance in cancer, but one of the most significant pathways is intracellular drug efflux and reduced drug concentrations within cells, which are controlled by overexpressed drug efflux pumps. As a member of the family of ABC transporter proteins, ABCC5 (ATP Binding Cassette Subfamily C Member 5) reduces the intracellular concentration of a drug and its subsequent effectiveness using an ATP-dependent method to pump the drug out of the cell. Numerous studies have demonstrated that ABCC5 is strongly linked to both poor prognosis and poor treatment response. In addition, elevated ABCC5 expression is noted in a wide variety of malignancies. Given that ABCC5 is regulated by several pathways in a broad range of cancer types, it is a prospective target for cancer treatment. This review examined the expression, structure, function, and role of ABCC5 in various cancer types.
癌症治疗中超过90%的治疗失败可归因于多药耐药性（MDR），其可在细胞内产生或通过多种途径形成。众多途径导致癌症治疗耐药，但最重要的途径之一是细胞内药物外排以及细胞内药物浓度降低，这是由过表达的药物外排泵控制的。作为ABC转运蛋白家族的一员，ABCC5（ATP结合盒转运体C亚家族成员5）通过依赖ATP的方法将药物泵出细胞，从而降低细胞内药物浓度及其后续疗效。大量研究表明，ABCC5与预后不良和治疗反应不佳密切相关。此外，在多种恶性肿瘤中均发现ABCC5表达升高。鉴于ABCC5在多种癌症类型中受多种途径调控，它是癌症治疗的一个潜在靶点。本综述研究了ABCC5在各种癌症类型中的表达、结构、功能及作用。
